| Literature DB >> 28368541 |
Julie Dyall1, Brit J Hart1, Elena Postnikova1, Yu Cong1, Huanying Zhou1, Dawn M Gerhardt1, Denise Freeburger1, Julia Michelotti1, Anna N Honko2, Lisa Evans DeWald1, Richard S Bennett1, Gene G Olinger1, Peter B Jahrling1,2, Lisa E Hensley1.
Abstract
Previous studies have demonstrated little efficacy of interferons (IFNs) in animal models of Ebola virus disease. However, these studies were limited to a small number of type I IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the animal models to evaluate IFNs were raised. To address the potential that anti-Ebola virus activity was overlooked, type I and type II IFNs (α-2a, α-2b, -β, -γ, and -universal) were tested in a variety of cell types (Vero E6, Huh 7 cells, and human macrophages). IFNs are weak inhibitors of Ebola virus Makona in these cell lines. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.Entities:
Keywords: Ebola virus; antiviral; interferon.
Mesh：
Substances：
Year: 2017 PMID： 28368541 PMCID： PMC5853567 DOI： 10.1093/infdis/jix134
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226